Keyphrases
COVID-19
100%
Mycobacterium Tuberculosis (M. tb)
73%
Finland
46%
Mycobacterial Species
41%
Antibody Detection
40%
Respiratory Symptoms
40%
Mycobacterium
40%
Fully Automated
40%
Automated Testing
40%
Age of Infection
40%
Rapid Antigen Test
40%
SARS-CoV-2 alpha Variant
40%
Beta Variant
40%
Incidence Trends
40%
Rifampicin Resistance
40%
Isoniazid Resistance
40%
MDR Tuberculosis
40%
Low Incidence
40%
Genotype
26%
Cross-reactivity
26%
Confidence Interval
22%
Phylogenetic Clustering
20%
Prevention Policies
20%
Alpha Variant
20%
Positive Percent Agreement
13%
Elecsys
12%
Clinical Evaluation
8%
Mycobacterial Identification
8%
Non-respiratory
8%
Viral
8%
Nucleic Acid Amplification Test
8%
SARS-CoV-2 Virus
8%
Respiratory Viruses
8%
Genus Level
6%
Progress Management
6%
Nontuberculous Mycobacterial Infection
6%
Clinical Culture
6%
Single Species
6%
Species Distribution
6%
Primary Identification
6%
Genotype Mycobacterium CM
6%
Mycobacterium Intracellulare
6%
Evaluation Report
6%
Mycobacterium Interjectum
6%
Mycobacterial Culture
6%
DNA Strips
6%
Species Level
6%
Strip Assay
6%
Result Interpretation
6%
Clinical Performance
6%
Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
97%
Mycobacterium Tuberculosis
45%
Spike
40%
Mycobacteria
40%
COVID-19
40%
Virus Nucleocapsid
40%
Nontuberculous mycobacteria
40%
Cross-Reactivity
38%
Respiratory Virus
13%
Virus
13%
Nucleic Acid Amplification
11%
Mycobacterium Intracellulare
5%
Species Distribution
5%
Species Identification
5%
Mycobacterium gordonae
5%
Seroconversion
5%
Mixed Cell Culture
5%
Serology
5%
Drug Sensitivity
5%
Medicine and Dentistry
Severe Acute Respiratory Syndrome Coronavirus 2
57%
Rifampicin
40%
Virus Nucleocapsid
40%
Mycobacterium Tuberculosis
40%
COVID-19
40%
Isoniazid
40%
Atypical Mycobacterium
40%
Sensitivity and Specificity
14%
Nucleic Acid Amplification
11%
Outpatient
5%
Drug Sensitivity
5%
Diagnosis
5%
Seroconversion
5%
Cross Reaction
5%
